头孢哌酮与莫西沙星治疗肺部感染的疗效对比

Cefoperazone vs. Moxifloxacin in the Treatment of Pulmonary Infection

目的:比较头孢哌酮与莫西沙星治疗肺部感染的疗效及其安全性。方法:共选入肺部感染住院患者120例,随机分为两组,其中应用头孢哌酮治疗60例、莫西沙星治疗60例。结果:头孢哌酮组有效率86.7%,莫西沙星组有效率93.3%;对致病菌株的清除率分别为83%和90.8%;不良反应发生率分别为5%与3.3%,两者临床疗效无明显差异(P>0.05)。结论:头孢哌酮与莫西沙星都是安全有效治疗肺部感染的药物。

OBJECTIVE：To evaluate the therapeutic efficacy and adverse reactions of cefoperazone vs.moxifloxacin for pulmonary infection.METHODS：120 inpatients with pulmonary infection were randomly assigned to receive cefoperazone（n=60） or moxifloxacin（n=60）.RESULTS：There were no significant differences between the cefoperazone group and the moxifloxacin group in clinical efficacy（P〉0.05）（effective rate：86.7% vs.93.3%;bacterial clearance rate：83% vs.90.8%;incidence of adverse reactions：5% vs.3.3%） CONCLUSION：Both cefoperazone and moxifloxacin are safe and effective for patients with pulmonary infection.